Kiadis Pharma orga­nizes a Satellite Symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation

Amsterdam, The Netherlands, March 24, 2014 – Kiadis Pharma B.V., a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing T-cell immunother­a­py treat­ments for blood can­cers, today announces that it will orga­nize a satel­lite sym­po­sium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Milan, Italy.
The satel­lite sym­po­sium host­ed by Kiadis Pharma is enti­tled: “Effective T-cell immunother­a­py with ATIR™ after hap­loiden­ti­cal HSCT: Excellent OS with low GvHD” and will take place on Sunday March 30 from 16.00-18.00 CET in Room Space 4. The event will be chaired by Dr. Armand Keating, Professor of Medicine at the University of Toronto, Canada. Dr. Keating is past pres­i­dent of the American Society of Hematology (ASH) and the American Society for Blood and Marrow Transplantation (ASBMT). The speak­ers are respect­ed key opin­ion lead­ers in the field of hap­loiden­ti­cal stem cell trans­plan­ta­tion and selec­tive pho­tode­ple­tion: Professor Irwin Walker (Hamilton, Canada), Professor Stephan Mielke (Würzburg, Germany), Professor Denis-Claude Roy (Montreal, Canada), Dr. Robert Preti (Allendale, USA) and Professor John Barrett (Bethesda, USA). The pro­gram includes an overview of cur­rent chal­lenges of alter­na­tive donor trans­plan­ta­tions, how selec­tive pho­tode­ple­tion can over­come these chal­lenges, and what the poten­tial of ATIR™ is in rela­tion to alter­na­tive trans­plan­ta­tion strate­gies using the pre­lim­i­nary results of the ongo­ing Phase II clin­i­cal study.
Additionally, the appli­ca­tion of Quality by Design dur­ing process devel­op­ment of ATIR™ will be dis­cussed, and how this result­ed in sta­ble and robust ATIR™ man­u­fac­tur­ing.

Leave a Reply

Your email address will not be published. Required fields are marked *